Mostrar el registro sencillo del ítem
Esclerosis múltiple en pacientes pediátricos: fisiopatología, diagnóstico y manejo
dc.contributor.author | Farfán Albarracín, Juan David | spa |
dc.contributor.author | Espitia Segura, Oscar Mauricio | spa |
dc.date.accessioned | 2020-10-27T14:20:23Z | |
dc.date.available | 2020-10-27T14:20:23Z | |
dc.date.issued | 2012-03-26 | |
dc.identifier.issn | 2382-4603 | |
dc.identifier.issn | 0123-7047 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12749/10201 | |
dc.description.abstract | Objetivo: Revisar la literatura disponible sobre esclerosis múltiple en la población pediátrica. Métodos: Revisión sistemática de la literatura encontrada en las bases de datos Scopus y PubMed posterior al año 2000.Resultados y Conclusiones: La Esclerosis Múltiple es una enfermedad con una tasa de incidencia de 2 – 4 / 100.000 habitantes en Colombia, de la cual la población pediátrica representa entre 2,7 – 5% de los casos. Las causas que se han atribuido a la enfermedad son múltiples, incluyendo factores ambientales como infecciones virales o bacterianas, exposición a humo de cigarrillo o deficiencia de vitamina D, entre otras, genéticas e inmunológicas. Su diagnóstico se basa en los hallazgos clínicos e imagenológicos, previa exclusión de enfermedades más comunes. Su tratamiento se divide en tres ejes: el tratamiento de eventos agudos, el tratamiento modificador de la enfermedad y el tratamiento sintomático. Para el primero los medicamentos de primera elección son los corticoides, para el segundo los medicamentos inmunomoduladores como Acetato de Glatiramer y para el tercero se debe realizar un enfoque multidisciplinario. Su pronóstico a largo plazo es variable y depende en alguna medida de la respuesta al tratamiento. | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | spa | spa |
dc.publisher | Universidad Autónoma de Bucaramanga UNAB | |
dc.relation | https://revistas.unab.edu.co/index.php/medunab/article/view/1524/1492 | |
dc.relation.uri | https://revistas.unab.edu.co/index.php/medunab/article/view/1524 | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | |
dc.source | MedUNAB; Vol. 14 Núm. 3 (2011): Infección Nosocomial, Precio de Medicamentos, Retinoblastoma; 167-179 | |
dc.title | Esclerosis múltiple en pacientes pediátricos: fisiopatología, diagnóstico y manejo | spa |
dc.title.translated | Pediatric multiple sclerosis: pathophysiology, diagnosis, and management | eng |
dc.publisher.faculty | Facultad Ciencias de la Salud | spa |
dc.publisher.program | Pregrado Medicina | spa |
dc.type.driver | info:eu-repo/semantics/article | |
dc.type.local | Artículo | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | |
dc.subject.keywords | Multiple sclerosis | eng |
dc.subject.keywords | Demyelinating autoimmune diseases | eng |
dc.subject.keywords | CNS | eng |
dc.subject.keywords | Pediatrics | eng |
dc.subject.keywords | Diagnosis | eng |
dc.identifier.instname | instname:Universidad Autónoma de Bucaramanga UNAB | spa |
dc.type.hasversion | Info:eu-repo/semantics/publishedVersion | |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.relation.references | Hauser SL, Goodin DS. Esclerosis Múltiple y otras enfermedadesdesmielinizantes.In:FauciAS,Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., editors. Harrison: Principios de MedicinaInterna.vol.II.17ed.McGraw-HillInteramericana Editores S.A.; 2009:2611-21 | spa |
dc.relation.references | Chitnis T. Pediatric multiple sclerosis. Neurologist 2006; 12:299-310 | spa |
dc.relation.references | Venkateswaran S, Banwell B. Pediatric multiple sclero-sis. Neurologist 2010; 16:92-105 | spa |
dc.relation.references | Sánchez JL, Aguirre C, Arcos-Burgos M, Jiménez-Ramírez I, Jiménez ME, León-Sarmiento FE, et al. Prevalencia de la esclerosis múltiple en Colombia. Rev Neurol 2000; 31:1101-3. | spa |
dc.relation.references | Padilla G, León-Sarmiento FE. Esclerosis múltiple en Colombia: cerrando la brecha. Acta Neurol Colomb 2007; 23:3-5 | spa |
dc.relation.references | Simpson S, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence ofmultiplesclerosis:ameta-analysis.JNeurolNeurosurg Psychiatry 2011; 82:1132-41 | spa |
dc.relation.references | Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis. Neurology 2008; 71:129-35. | spa |
dc.relation.references | Yeh EA, Chitnis T, Krupp L, Ness J, Chabas D, Kuntz N, et al. Pediatric multiple sclerosis. Nat Rev Neurol 2009; 5:621-31 | spa |
dc.relation.references | Bar-Or A. Immunology of multiple sclerosis. Neurol Clin 2005; 23:149-75. | spa |
dc.relation.references | Frohman EM, Racke MK, Raine CS. Multiple sclerosis - The plaque and its pathogenesis. N Engl J Med 2006; 354:942-55 | spa |
dc.relation.references | Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiplesclerosisinchildren:clinicaldiagnosis,therapeutic strategies, and future directions. Lancet Neurol 2007; 6:887-902 | spa |
dc.relation.references | Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7:268-77. | spa |
dc.relation.references | Oksenberg JR, Hauser SL. Genetics of multiple sclero-sis. Neurol Clin 2005; 23:61-75 | spa |
dc.relation.references | Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-81. | spa |
dc.relation.references | Goodin DS. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS ONE 2009; 4:e4565 | spa |
dc.relation.references | Giovannoni G, Cutter GR, Lunemann J, Martin R, Munz C, Sriram S, et al. Infectious causes of multiple sclerosis. Lancet Neurol 2006; 5:887-94 | spa |
dc.relation.references | Waldman A, O'Connor E, Tennekoon G. Childhood multi-ple sclerosis: Areview. Mental Retardat Dev Dis Res Rev 2006; 12:147-56 | spa |
dc.relation.references | Tenembaum S. Encefalomielitis aguda diseminada y es-clerosis múltiple en pediatria. Acta Neurol Colomb 2006; 22:163-79 | spa |
dc.relation.references | Ozakbas S, Idiman E, Baklan B, Yulug B. Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features. Brain Dev 2003; 25:233-6 | spa |
dc.relation.references | Belman AL, Chitnis T, Renoux C, Waubant E, for the International Pediatric MS Study Group. Challenges in the classification of pediatric multiple sclerosis and future directions. Neurology 2007; 68(16 suppl 2):S70-S74 | spa |
dc.relation.references | Krupp LB, Banwell B, Tenembaum S, for the Interna-tional Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68(16 suppl 2):S7-S12 | spa |
dc.contributor.cvlac | Farfán Albarracín, Juan David [0001497529] | spa |
dc.contributor.cvlac | Espitia Segura, Oscar Mauricio [0000006586] | spa |
dc.contributor.googlescholar | Farfán Albarracín, Juan David [z3Vat94AAAAJ&hl=es&oi=ao] | spa |
dc.contributor.googlescholar | Espitia Segura, Oscar Mauricio [kXq5uSsAAAAJ&hl=es&oi=ao] | spa |
dc.contributor.orcid | Farfán Albarracín, Juan David [0000-0002-2905-645X] | spa |
dc.contributor.orcid | Espitia Segura, Oscar Mauricio [0000-0002-3706-4951] | spa |
dc.subject.lemb | Ciencias de la salud | spa |
dc.subject.lemb | Medicina | spa |
dc.subject.lemb | Ciencias medicas | spa |
dc.identifier.repourl | repourl:https://repository.unab.edu.co | |
dc.description.abstractenglish | Objective: Review the available literature on multiple sclerosis in the pediatric population. Methods: Systematic review of the literature found in the Scopus and PubMed databases after the year 2000. Results and Conclusions: Multiple Sclerosis is a disease with an incidence rate of 2 – 4 / 100,000 inhabitants in Colombia, of which the pediatric population represents between 2.7 – 5% of cases. The causes that have been attributed to the disease are multiple, including environmental factors such as viral or bacterial infections, exposure to cigarette smoke or vitamin D deficiency, among others, genetic and immunological. Its diagnosis is based on clinical and imaging findings, after exclusion of more common diseases. Its treatment is divided into three axes: treatment of acute events, disease-modifying treatment and symptomatic treatment. For the first, the first choice medications are corticosteroids, for the second, immunomodulatory medications such as Glatiramer Acetate, and for the third, a multidisciplinary approach must be carried out. Its long-term prognosis is variable and depends to some extent on the response to treatment. | eng |
dc.subject.proposal | Esclerosis múltiple | spa |
dc.subject.proposal | Enfermedades autoinmunes desmielinizantes | spa |
dc.subject.proposal | SNC | spa |
dc.subject.proposal | Pediatría | spa |
dc.subject.proposal | Diagnóstico | spa |
dc.type.redcol | http://purl.org/redcol/resource_type/ART | |
dc.rights.creativecommons | Atribución-NoComercial-SinDerivadas 2.5 Colombia | * |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Revista MedUNAB [817]